3 stories mentioning HKG:2269Updated 6d ago
Every FINWIRES story that references HKG:2269, newest first.
WuXi Biologics (Cayman) (HKG:2269) has an average rating of overweight and mean price target of HK$48.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
CANbridge Pharmaceuticals (HKG:1228) entered service procurement framework agreements with WuXi Biologics and Baheal Medical, according to a Tuesday Hong Kong bourse filing.Under the agreement, WuXi Biologics (HKG:2269) will provide contract research, development, and manufacturing organization services to CANbridge through 2028.Meanwhile, Baheal Medical will provide logistics, warehousing, and other supporting services through 2028.
WuXi Biologics (Cayman) (HKG:2269) said it plans to buy back up to $400 million of its shares from the open market, according to a filing with the Hong Kong bourse.The company said its current share price does not reflect its intrinsic value, representing a good opportunity to conduct the buyback.The company's shares were up over 4% in recent morning trade.
